Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sino Biopharm Ord (OP:SBMFF)

0.6017 -0.0314 (-4.96%)
Streaming Delayed Price Updated: 12:40 PM EDT, Jun 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sino Biopharm Ord

News headline image
Sino Biopharm (1177.HK) Announces 2025 Annual Results
From Sino Biopharmaceutical Limited
Via ACN Newswire
News headline image
Sino Biopharm (1177.HK) Announces 2025 Interim Results
From Sino Biopharmaceutical Limited
Via ACN Newswire
News headline image
Sino Biopharm (1177.HK) Announces 2024 Annual Results
From Sino Biopharmaceutical Limited
Via ACN Newswire
News headline image
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
From Sino Biopharmaceutical Limited
Via ACN Newswire
News headline image
Strong Consumer Turnout Drives Hong Kong Stocks Higher Friday As China's Former Premier Li Keqiang Dies At 68 ↗
Hong Kong stocks rallied Friday as the week closed out higher for consumer stocks and EV makers which investors hope will be the beneficiary of a forthcoming government stimulus.   The Hang Seng Index... 
Via Benzinga
News headline image
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million ↗
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product... 
Via Talk Markets
News headline image
Week In Review: Sino Biopharma Acquires F-Star For $161 Million After US Approval ↗
Sino Biopharma was approved to close its $161 million all-cash acquisition of F-Star. The purchase didn't look like would happen after it was held up for nine months by the US government’s Committee on... 
Via Talk Markets
News headline image
Week In Review: China Life Science Posts $1.3 Billion In Deals ↗
Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome for up to $800 million. Zai Lab and Schrödinger formed a collaboration to develop a... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.